The Journal of infectious diseases · 2026
Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tam Kingsley King-Gee, Suster Carl J E, Fong Winkie, Golubchik Tanya, Sivalingam Varsha, Jeoffreys Neisha, Tay Enoch, Ko Danny, Wehrhahn Michael C, Ginn Andrew N, Robson Jennifer, Gardner Indya, Papanicolas Lito E, Kennedy Karina, Graham Maryza, Tran Thomas, Speers David, Cooley Louise, Baird Rob W, Meumann Ella M, Harbidge Jaimee, Campbell Stuart, Basile Kerri, Chen Sharon C A, Sintchenko Vitali, Kok Jen, Rockett Rebecca J
Аннотация
BACKGROUND: The resurgence of Mycoplasma pneumoniae, first reported in China in 2023, was attributed to waning postpandemic immunity with increases in macrolide-resistant M. pneumoniae (MRMP) (> 80%). In Australia, infections peaked in early 2024, particularly among children under 15 years. While MRMP remains low in Europe, North America, and Australia (< 5%), limited routine testing restricts understanding of resistance dynamics. As macrolides are first-line therapy in many settings, MRMP surveillance is essential for guiding empirical treatment.
METHODS: We applied a capture-based targeted metagenomic sequencing (targeted next-generation sequencing [tNGS]) to polymerase chain reaction (PCR)-positive M. pneumoniae specimens (n = 356) from across Australia. This approach enabled whole-genome recovery and MRMP detection directly from clinical specimens, without culture. MRMP detections were benchmarked against PCR and data were analyzed to assess associations between resistance and health care utilization.
RESULTS: This is the first genomics-informed national study of M. pneumoniae in Australia. We recovered 124 high-quality genomes, revealing a genetically diverse population with cocirculation of P1 type 1 (69%) and type 2 (31%). MRMP was identified in 13% of genomes, all belonging to clades that prior to 2024 had only been reported in Asia (ST3 and ST14). MRMP cases were geographically widespread, suggesting importation and local transmission. Unlike reports from China, macrolide-susceptible clades (ST3, ST7, ST17, and ST20) predominated (87%) and were associated with significantly lower health care utilization compared to MRMP cases.
CONCLUSIONS: Our findings demonstrate the utility of tNGS for genomic epidemiology and highlight the need for MRMP surveillance. Although macrolides remain effective in Australia, emerging MRMP strains require close monitoring to inform treatment guidelines and antimicrobial stewardship.
METHODS: We applied a capture-based targeted metagenomic sequencing (targeted next-generation sequencing [tNGS]) to polymerase chain reaction (PCR)-positive M. pneumoniae specimens (n = 356) from across Australia. This approach enabled whole-genome recovery and MRMP detection directly from clinical specimens, without culture. MRMP detections were benchmarked against PCR and data were analyzed to assess associations between resistance and health care utilization.
RESULTS: This is the first genomics-informed national study of M. pneumoniae in Australia. We recovered 124 high-quality genomes, revealing a genetically diverse population with cocirculation of P1 type 1 (69%) and type 2 (31%). MRMP was identified in 13% of genomes, all belonging to clades that prior to 2024 had only been reported in Asia (ST3 and ST14). MRMP cases were geographically widespread, suggesting importation and local transmission. Unlike reports from China, macrolide-susceptible clades (ST3, ST7, ST17, and ST20) predominated (87%) and were associated with significantly lower health care utilization compared to MRMP cases.
CONCLUSIONS: Our findings demonstrate the utility of tNGS for genomic epidemiology and highlight the need for MRMP surveillance. Although macrolides remain effective in Australia, emerging MRMP strains require close monitoring to inform treatment guidelines and antimicrobial stewardship.